

1 Probiotics: a proactive approach to health. A symposium report

2 Linda V. Thomas^{1*}, Kaori Suzuki² and Jia Zhao²

3 ¹*Yakult UK Limited, Odyssey Business Park, West End Road, South Ruislip, Middlesex HA4 6QQ, UK*

4 ²*Yakult Europe B.V., Schutsluisweg 1, 1332 EN Almere, The Netherlands*

5 *(Submitted 31 July 2015 – Final revision received 27 August 2015 – Accepted 10 September 2015)*

7 Abstract

8 This report summarises talks given at the 8th International Yakult Symposium, held on 23–24 April 2015 in Berlin. Two presentations explored
9 different aspects of probiotic intervention: the small intestine as a probiotic target and inclusion of probiotics into integrative approaches to
10 gastroenterology. Probiotic recommendations in gastroenterology guidelines and current data on probiotic efficacy in paediatric patients were
11 reviewed. Updates were given on probiotic and gut microbiota research in obesity and obesity-related diseases, the gut–brain axis and
development of psychobiotics, and the protective effects of equol-producing strains for prostate cancer. Recent studies were presented
on probiotic benefit for antibiotic-associated diarrhoea and people with HIV, as well as protection against the adverse effects of a short-term
high-fat diet. Aspects of probiotic mechanisms of activity were discussed, including immunomodulatory mechanisms and metabolite effects,
the anti-inflammatory properties of *Faecalibacterium prausnitzii*, the relationship between periodontitis, microbial production of butyrate in
the oral cavity and ageing, and the pathogenic mechanisms of *Campylobacter*. Finally, an insight was given on a recent expert meeting, which
re-examined the probiotic definition, advised on the appropriate use and scope of the term and outlined different probiotic categories and the
prevalence of different mechanisms of activity.

Key words: Probiotics: Gut microbiota: Immune system: Irritable bowel syndrome: Diarrhoea: Diabetes: Cancer

20 The 8th International Yakult Symposium, held on 23–24 April
21 2015 in Berlin, was entitled ‘Probiotics, a proactive approach to
22 health’. The title was chosen for two reasons: to emphasise the
23 importance of taking steps to maintain health throughout life
24 and, because the gut microbiota has a major influence on the
25 whole body (not just on the gut), its modulation by probiotics can
26 be part of a strategy for achieving this. This report summarises the
27 talks given by the panel of international expert speakers, who
28 covered different aspects of microbiology, gastroenterology,
29 immunology as well as metabolic and infectious disease. All
30 speakers approved the manuscript before submission.

31 Aspects of probiotic intervention

32 *The small intestine: a target for probiotics*

33 The primary message from Professor Michiel Kleerebezem
34 (Wageningen University, The Netherlands) was that the small
35 intestine is pivotal for health⁽¹⁾. With its distinct community of
36 commensal microbiota and concentration of immune cells, it is
37 a key target for probiotic intervention. Analysis of its microbiota,
38 however, has been hampered by a lack of non-invasive sampling

39 methods for healthy volunteers: sampling has usually been
40 carried out via naso-ileal catheters. Although luminal microbiota
41 samples are easily obtained from the distal ileum of ileostomy
42 subjects, these are usually inflammatory bowel disease (IBD) or
43 cancer patients.

44 Newly developed radio-controlled capsules (IntelliCap[®]) are
45 currently being evaluated for the extraction of small volume
46 samples (100–200 µl) from the small intestine of healthy
47 volunteers, to avoid the use of invasive technologies or causing
48 undue discomfort⁽²⁾.

49 16S rRNA phylogenetic microarray (The Human Intestinal Tract
50 Chip) analysis of the ileostomal, small intestine and faecal sam-
51 ples has found that the gut microbiota of the small intestine is
52 much simpler than that of the colon, with far fewer species^(3–5).
53 Ileostomy samples can serve as models for the microbiota of
54 the proximal small intestine, as the microbial compositions are
55 reasonably similar⁽⁶⁾. Predominant genera in the small intestine
56 are *Streptococcus*, *Veillonella*, *Clostridium* and *Escherichia*⁽⁷⁾.
57 Metagenomic and metatranscriptomic studies have confirmed
58 that the small intestinal microbiota is strongly focused on the
59 import and fermentation of simple carbohydrates⁽⁶⁾. *Escherichia*
60 and *Streptococcus* spp. seem to be involved in carbohydrate

Abbreviations: AAD, antibiotic-associated diarrhoea; BA, butyric acid; CD, Crohn's disease; FMT, faecal microbiota transplant; GI, gastrointestinal; IBD, inflammatory bowel disease; IBS, irritable bowel syndrome; LPS, lipopolysaccharide; PC, prostate cancer; RCT, randomised-controlled trials; SCI, spinal cord injury; T2D, type 2 diabetes; TLR, toll-like receptor; UC, ulcerative colitis.

* **Corresponding author:** L. V. Thomas, email LThomas@yakult.co.uk

import, using phosphotransferase transport systems to convert carbohydrates to pyruvate by glycolysis, and then converting this intermediate to the fermentation end products such as lactate, acetate, formate and potentially ethanol. The secondary fermentation of lactate and acetate by *Veillonella* and *Clostridium* spp. produces propionate, acetate and butyrate. As lactobacilli are not dominant in the small intestine, probiotics have the potential to overcrowd the endogenous microbiota and cause a dramatic, albeit transient, community shift that cannot be achieved in the densely colonised colon.

A pioneering study on healthy men revealed a significant host mucosal transcription response to ingestion of probiotic lactobacilli in the small intestine, with 300–750 genes affected in a strain-specific manner^(8,9). Network biology approaches for transcriptome data interpretation have now advanced sufficiently to enable a molecular explanation of the clinical outcome of a *Lactobacillus* intervention. Moreover, the *in vivo* data also confirmed specific wound healing-accelerating effects of the probiotic *Lactobacillus rhamnosus* GG (LGG) on mucosal physiology, which are achieved through previously established secretion of the proteins P40 and P75 that modulate epidermal growth factor-receptor signalling⁽¹⁰⁾. These analyses may also be employed to predict physiological consequences using comparative transcriptomic analyses, which have established significant correlation of responses to probiotics with responses measured for pharmaceutical drugs⁽¹¹⁾. It should be noted, however, that most of these pharmaceuticals work systemically, whereas probiotics work locally in the gut. Nevertheless, some probiotic effects and mechanisms may be similar to those achieved by specific drugs and may provide guidance to future probiotic intervention trials.

There is considerable variation in people's responses to any probiotic; probiotic-responsive genes also cluster according to individual and not by intervention^(8,12). Volunteers for a probiotic trial may be considered healthy yet actually vary enormously in the molecular makeup of their mucosa, indicating that differential molecular solutions for health are possible and can influence the responsiveness to a probiotic intervention, which may (in part) explain 'non-responders' in probiotic trials. How this molecular individuality of human subjects is achieved remains unclear and could include many factors such as genotype, epigenetic imprinting, dietary habits, lifestyle and/or endogenous microbiota. Professor Kleerebezem underlined the importance of a crossover trial design, and for probiotic intervention studies exemplified the potential of subject stratification prior to enrolment, on the basis of their predicted susceptibility to the intervention being tested.

Probiotics as part of an integrative approach to gastroenterology

Professor Jost Langhorst (Kliniken Essen-Mitte, Germany) explained that IBD, irritable bowel syndrome (IBS) and other gastrointestinal (GI) diseases are driven by multiple factors, including genetic predisposition, immune dysregulation, gut dysbiosis and barrier dysfunction. Crohn's disease (CD) patients, for example, have a low diverse gut microbiota with reduced *Faecalibacterium prausnitzii* and increased

Escherichia coli. Relatives of the patients, with the same CD genetic disposition, also showed some degree of dysbiosis and gut barrier abnormality⁽¹³⁾. As several microbial-related factors (e.g. dysbiosis and low microbiota diversity, presence/persistence of pathobiont presence and pathogenic antigens) link a defective mucosal interface to inflammation^(14,15), the gut microbiota should be a treatment target⁽¹⁶⁾.

Professor Langhorst recommended an integrative approach to chronic GI disorders, combining evidence-based complementary and alternative medicine (CAM) with mainstream medicine and lifestyle modifications. Health-care professionals also need to keep up to date with CAM as patients with chronic GI disorders explore and ask about all available treatments⁽¹⁷⁾. As an example, botanical therapies used in IBD were reviewed by Professor Langhorst. Psyllium, for example, may be as effective as mesalazine in prolonging remission in ulcerative colitis (UC)⁽¹⁸⁾ and also showed effectiveness for active CD when used in combination with probiotics⁽¹⁹⁾. Other plants and plant-derived substances investigated are the following: curcumin; frankincense; a combination of myrrh, chamomile and charcoal; bilberries; tormentil; and wormwood⁽²⁰⁾. Results on psyllium and curcumin are now positive enough to warrant mention in German UC guidelines⁽²¹⁾. Cannabis, a strongly regulated and controlled substance, is also of interest with IBD, but side effects are frequent, and there may be a higher risk of surgery in CD⁽²²⁾. Traditional Chinese medicine is also of interest in IBD: acupuncture has shown benefit⁽²³⁾.

In industrialised countries, lifestyle and environmental factors have a strong influence on IBD⁽²⁴⁾, and these factors (e.g. smoking and lack of exercise) may also influence the gut microbiota^(25,26). Mind–body interventions are also used in treatment of chronic GI disorders because of the evidence that stress exacerbates IBD symptoms^(27,28). Stress reduction strategies and mind–body therapy have shown benefit in UC^(29,30), and stress can also change the composition of the commensal microbiota⁽³¹⁾. Such observations are part of the rationale for exploring probiotic benefit for IBD. Certain strains have shown benefit (e.g. *E. coli* Nissle, lactobacilli, bifidobacteria and streptococci) in maintaining remission in UC and acute pouchitis, but there is no reliable evidence for CD. Patients are interested in another strategy for gut microbiota modulation – faecal microbiota transplant (FMT) – and may even attempt it themselves. FMT capsules or microbial consortium have now been developed, and a stool bank facility has been established in the USA (<http://www.openbiome.org/>). Although FMT has shown positive effects with recurrent *Clostridium difficile* infection⁽³²⁾, results have been more uneven in IBD^(33,34). Two recent randomised studies of patients with active UC have been conducted: one had no effect, and one was effective in inducing remission^(35,36).

Guidelines and recommendations for probiotic usage

Gastroenterology guidelines for irritable bowel syndrome

Professor Viola Andresen (Israelitic Hospital, Germany) explained that guidelines are a combination of medical science, clinical practice and education intended to help promote good clinical practice and to inform the public. Guidelines also need

to ensure cost-effectiveness and support clinical decisions and may even be used in legal disputes. The guidelines in Germany are decided by expert opinion alone or by consensus following the Delphi process⁽³⁷⁾, as well as by evaluation of evidence found by a systematic search and review of the literature, which considers risk of bias, inconsistency, indirectness and imprecision. Recommendations are based on the Grading of Recommendations Assessment, Development and Evaluation approach⁽³⁸⁾. Even if no evidence is available, an expert opinion may still be needed.

The rationale for probiotic use in IBS is based on the role of the gut microbiota in many GI functions and the observation of a disturbed microbiota in patients. The difficulty in evaluating efficacy, however, was illustrated by studies with *Bifidobacterium longum* subsp. *infantis* 35624. A 2005 trial reported alleviation of symptoms⁽³⁹⁾, yet a later study did not find benefit at this test level (10^{10} colony-forming units (CFU)) but did with a lower dosage (10^8 CFU)⁽⁴⁰⁾. Despite conflicting results, meta-analyses do suggest probiotic benefit, but the data raise several questions^(41,42). More research is needed to determine mechanisms of actions, which probiotics are effective and at what dosage and duration.

Several countries now mention probiotics in their clinical guidance on IBS. Although the American Gastroenterological Association IBS management guidelines do not cover probiotics, the accompanying technical review indicates that probiotics may be beneficial and can be considered on an individual basis⁽⁴³⁾. A related and more comprehensive review concluded that, as a whole, probiotics improve global symptoms, bloating and flatulence, but this was a weak recommendation based on low quality of evidence⁽⁴²⁾. The UK's National Institute for Health and Care Excellence does not directly recommend probiotics but does offer advice to people who choose to take them – to take probiotics for at least 4 weeks at the manufacturer's recommended dose while monitoring the effect⁽⁴⁴⁾. German guidelines recommend that selected probiotics can be used for treatment, with the strain selection based on symptoms⁽⁴⁵⁾.

Professor Andresen finished by noting the strain-specific nature of probiotics and the heterogeneous nature of available studies. She also discussed whether probiotics should be classified as food or medicine, and their acceptance by experts. Finally, she underlined that the potential success of gut microbiota modulation for IBS was underlined by a case report of a patient who had suffered post-infectious IBS for 2 years, which was refractory to any conventional treatment. The patient became symptom-free within hours of undergoing FMT and remained healthy 14 months later.

Probiotic efficacy in paediatrics: a review of the evidence

After noting the problem of the strain-specific nature of probiotic benefit for meta-analyses and systematic analyses, Professor Hania Szajewska (The Medical University of Warsaw, Poland) gave a comprehensive update of this area.

- Treatment of acute gastroenteritis: in 2014, the European Society for Paediatric Gastroenterology Hepatology and

Nutrition published an evidence-based position paper, concluding that use of probiotics with documented efficacy may be considered⁽⁴⁶⁾. The use of the following probiotics may be considered as adjuncts to standard oral rehydration therapy for reducing diarrhoea duration: LGG or the yeast species *Saccharomyces boulardii* (low quality of evidence for both strains; strong recommendation); and *Lactobacillus reuteri* DSM 17938 (low quality of evidence; weak recommendation). There was insufficient evidence to recommend any of the many other probiotics that have been studied.

- Prevention of nosocomial diarrhoea: some, but not all, probiotics have shown efficacy^(47,48), particularly for GI infections. A recent study with *Bifidobacterium animalis* subsp. *lactis* failed to show prevention of common infections in hospitalised children⁽⁴⁹⁾.
- Prevention of antibiotic-associated diarrhoea (AAD): although there was no evidence to support probiotics as a treatment, a recent meta-analysis that identified sixteen randomised-controlled trials (RCT) in children concluded an overall relative risk (RR) of 0.55 (95% CI 0.38, 0.8) for AAD prevention, with a number needed to treat (NNT) of 12⁽⁵⁰⁾.
- Prevention of necrotising enterocolitis (NEC): a recent Cochrane review calculated an RR of 0.43 (95% CI 0.33, 0.56) for probiotics in preventing NEC, and an RR of 0.65 (95% CI 0.52, 0.81) for death⁽⁵¹⁾. The NNT was approximately 33. The evidence is sufficiently strong enough to support a change in practice. Probiotics with documented efficacy may be considered for prevention of NEC, particularly where incidence is high. More information is needed to establish as to which products are effective, as well as their recommended dosages and duration of use.
- Infantile colic: there is evidence that *L. reuteri* DSM 17938 has benefit for infantile colic^(52,53). (One study reported no benefit, possibly due to participants' heterogeneity⁽⁵⁴⁾.) A recent meta-analysis of three RCT concluded that the probiotic is likely to reduce crying time by about 43 min (a welcome benefit for parents), especially in exclusively or predominantly exclusively breast-fed infants⁽⁵⁵⁾. A recent RCT suggested that *L. reuteri* DSM 17938 is also effective in preventing infantile colic; the probiotic reduced crying time from 71 to 38 min⁽⁵⁶⁾.
- Prevention of allergic disease: in 2015, the World Allergy Organization published new evidence-based guidelines relating to probiotic use⁽⁵⁷⁾. Current evidence does not indicate that probiotics reduce the risk of children developing allergy, but, despite very poor quality of evidence, it was recommended that there is a likely net benefit from probiotic use in pregnant women who are at high risk of having an allergic child, in women who breast-feed infants that are at high risk of allergy and in infants who are at high risk of developing allergy. However, it remains unclear which probiotic(s) should be used.

Professor Szajewska concluded that the composition of the gut microbiota plays a significant role in the development of a number of disorders affecting children. Although there is huge potential for probiotics, many questions still need to be answered.

Probiotic benefits for other conditions: an update on the evidence

Obesity and obesity-related disease

Professor Mauro Serafini (CRA-NUT, Italy) explained how a Western high-fat diet induces a sustained postprandial state of hyperlipidaemia and hyperglycaemia. This triggers cellular inflammation as well as oxidative stress due to the generation of reactive oxygen species. In turn, these cause endothelial damage and insulin resistance, which increases the risk for diseases such as the metabolic syndrome, atherosclerosis, type 2 diabetes (T2D), hypertension and stroke^(58–60).

A recent placebo-controlled study on healthy overweight people by Professor Serafini's group demonstrated that a dietary intervention in the form of fruit juice prevented an increase in plasma levels of pro-inflammatory cytokines (TNF- α , IL-6 and IL-17) that occurred after eating a high-fat meal⁽⁶¹⁾. Further studies have shown that eating high-fat meals increases plasma levels of uric acid and thiols; this also can be prevented by simultaneous consumption of fruit juice^(60,62). These effects may be due to the presence of flavonoid in the fruit juice; these plant metabolites are found in many foods⁽⁶³⁾. Flavonoid bioavailability *in vivo* (i.e. their antioxidant capability within the human body) can vary enormously in different types of food and can also differ significantly from antioxidant levels detected by *in vitro* testing of the food. Polyphenol flavonoids found in chocolate, for instance, have high antioxidant levels, but the interference of milk with their absorption *in vivo* explains why dark chocolate has a far greater antioxidant benefit *in vivo*⁽⁶⁴⁾. After ingestion, as well as being digested by host enzymes, dietary polyphenols are metabolised by the gut microbiota to produce a range of bioactive derivatives that can be absorbed by the intestinal cells^(65,66). The profile of bacterial species present in any individual's gut microbiota determines what bioactive metabolites will be derived from dietary polyphenols.

There is potential for probiotics to enhance microbial production of bioactive flavonoid metabolites in the gut⁽⁶⁷⁾. Several animal studies have also indicated that certain *Lactobacillus* and *Bifidobacterium* probiotic strains can reduce oxidative stress via mechanisms such as reducing hydrogen peroxide and hydroxyl radicals^(68–72). The one human study conducted to date showed a similar positive trend: consumption of a probiotic yogurt improved the antioxidant status of people with T2D⁽⁷³⁾.

Professor Nathalie Delzenne (Catholic University Louvain, Belgium) suggested the gut dysbiosis as a target for management of obesity and related disorders⁽⁷⁴⁾. In obese and overweight people, a gut microbiota of low diversity has been linked to these people's propensity for metabolic disturbances and chronic low-grade inflammation⁽⁷⁵⁾. Animal models show that the aberrant microbiota, often with lower levels of bifidobacteria and *Akkermansia muciniphila*, triggers disruption to the gut barrier, increasing permeability and promoting translocation of bacteria lipopolysaccharide (LPS) to cause endotoxaemia^(76,77). In diet-induced obese mice, live *A. muciniphila* administration decreased serum LPS, reduced adipose tissue inflammation and increased expression of the antimicrobial peptide RegIII γ in the colon. This intervention also reverses the thinning of the mucus layer observed in obesity⁽⁷⁷⁾. Obesity-related disease is also

associated with an altered profile of microbial metabolites, such as lower levels of SCFA and bile salt hydrolases, and raised numbers of sulphide-reducing bacteria. Recent animal studies also underline the ability of the gut microbiota to metabolise dietary PUFA⁽⁷⁸⁾.

In diet-induced obese animals, probiotic administration results in loss of body weight and/or fat mass and may also improve blood lipid levels, glycaemia or other metabolic disorders^(79–82). In mice fed a high-fat diet, probiotics shifted the aberrant gut microbiota profile towards that of lean mice on a normal diet. Strains differentially attenuated the induced obesity, inflammation and the metabolic syndrome⁽⁸³⁾. Human studies, however, have not been as convincing. Only a few have shown probiotic benefit, with only minor effects on the body weight and fat mass but better effects on blood lipids and metabolic response to diet^(84–86). A recent study with *Lactobacillus casei* Shirota has indicated the potential of certain probiotics in a preventative strategy for overfeeding-induced insulin resistance⁽⁸⁷⁾; however, Professor Delzenne recommended development of novel commensal strains as well as butyrate-producing⁽⁸⁸⁾ and CLA-producing probiotics⁽⁸⁹⁾.

Prebiotics affect not just bifidobacteria numbers but also the overall richness and diversity of microbial functions and species in the gut. Obesity studies in mice have shown that prebiotics changed the ratio of Firmicutes:Bacteroidetes and modified over 100 microbial taxa⁽⁹⁰⁾. High-fat diet and prebiotic intervention also influence host antimicrobial peptides⁽⁹¹⁾ and gut endocrine function⁽⁹²⁾. A 2013 review, which identified six prebiotic trials in overweight or obese people and three in non-alcoholic steatohepatitis or T2D, concluded that prebiotics increased feelings of satiety and reduced postprandial plasma glucose and insulin concentrations⁽⁹³⁾. Effects of prebiotics on endotoxaemia, fat mass, gut hormones, cardiovascular and hepatic health were also reported, which may be linked to microbial changes. A study on obese women found that an inulin-type fructans changed the gut microbiota by increasing levels of *Bifidobacterium* and *F. prausnitzii* (which correlated with reduced serum LPS) and reducing *Bacteroides intestinalis*, *Bacteroides vulgatus* and *Propionibacterium* (which correlated with slight decreases in fat mass, and plasma lactate and phosphatidylcholine levels)⁽⁹⁴⁾. Another study on obese women showed levels of *B. longum* and *A. muciniphila* correlated with reductions in plasma LPS, and *Bifidobacterium adolescentis* with decreases in fat mass. Perhaps surprisingly, the prebiotic also decreased SCFA levels (raised SCFA could be a metabolic risk factor for obese women)⁽⁹⁵⁾. The observed link between some PUFA-derived bacterial metabolites (e.g. CLA), certain gut species and host metabolism is not yet fully understood⁽⁹⁶⁾.

Dr Carl Hulston (Loughborough University, UK) continued the theme of the gut microbiota's influence on obesity and T2D^(97,98) in a short talk on his recent study into the effects of a probiotic on health risks associated with poor diet⁽⁸⁷⁾. In an RCT, a test group drank an *L. casei* Shirota fermented milk twice daily for 4 weeks, whereas a control group received no supplementation. All ate their normal diet for 3 weeks and then consumed a high-fat high-energy diet for 1 week. Compared with baseline, the week of overfeeding resulted in an increase of glucose AUC in an oral glucose tolerance test and elevated

439 fasting plasma glucose, as well as a decrease in insulin sensitivity
 400 for the control group, whereas all these parameters were main-
 401 tained in the probiotic group. Fasting serum insulin did not
 402 change in either group. These results suggest that probiotics may
 403 be useful in preventing diet-induced metabolic diseases but need
 404 to be confirmed in a larger study; the mechanism of activity also
 405 needs to be investigated.

406 *Manipulation of the gut–brain axis: the emergence of*
 407 *psychobiotic therapy*

408 Professor John Cryan (University College Cork, Ireland)
 409 reviewed research into the microbiota–gut–brain axis and
 410 explained that the gut microbiota is considered ‘the conductor
 411 of the orchestra of immune–neuroendocrine communication’,
 412 essential for normal stress, antidepressant and anxiety
 413 responses^(99,100). Unfortunately, the majority of evidence in this
 414 field is still from animal studies: either germ-free, subjected to
 415 early-life modulation of the gut microbiota, or exposed to
 416 specific pathogens, probiotics or antibiotics⁽¹⁰¹⁾. These studies
 417 have shown that stress in early life not only alters behaviour but
 418 also causes key changes in the immune system and the gut
 419 microbiota, which are themselves linked to changes in colonic
 420 transit time and morphology, intestinal permeability and
 421 mucosal inflammation^(102,103). Perturbation of the postnatal
 422 microbial colonisation process affects neurodevelopment, with
 423 possible consequences for later mental health⁽¹⁰⁴⁾.

424 The gut microbiota influences the brain and nervous system
 425 via several routes, including the vagus nerve, the spinal cord, and
 426 the immune and neuroendocrine systems. Gut bacteria produce
 427 several neuroactive molecules – for example, γ -aminobutyric
 428 acid, serotonin, catecholamines and acetylcholine⁽¹⁰⁵⁾ – and may
 429 also affect the early development of the hypothalamic–pituitary–
 430 adrenal reaction to stress⁽¹⁰⁶⁾. The importance of the gut
 431 microbiota for brain development and behaviour is clearly
 432 shown by germ-free animals, which display less anxiety and
 433 neurochemical differences^(107,108). Male germ-free animals
 434 show changes in the hippocampal serotonergic system, not
 435 reversible with restoration of the gut microbiota⁽¹⁰⁹⁾. Animal
 436 models have also shown that the gut microbiota influences
 437 regulation of neurogenesis in the adult hippocampus⁽¹¹⁰⁾ and
 438 blood–brain barrier permeability (reversible with the introduction
 439 of butyrate-producing bacteria)⁽¹¹¹⁾. It may also act as an
 440 epigenetic regulator of brain function, which may have a bearing
 441 on neurodevelopmental disorders such as autism. SCFA such as
 442 butyrate can alter the function of enzymes that modify histone
 443 proteins, thus changing gene expression⁽¹¹²⁾.

444 Development of probiotics with psychotropic effects would
 445 be facilitated by charting developmental events in the brain
 446 through life and relating this to parallel changes in the gut
 447 microbiota and its metabolites⁽¹⁰⁴⁾. Animal studies indicate the
 448 benefit of lactobacilli and bifidobacteria probiotics, with the
 449 vagus nerve as the key route for effects^(113,114).

450 Dysbiosis may be an underlying factor in the gut problems
 451 frequently experienced by people with autism spectrum
 452 disorder (ASD). The gut microbiota is essential for normal social
 453 development in mice⁽¹¹⁵⁾, and alterations in the gut microbiota
 454 and function were associated with autism-like behaviour in a

455 murine ASD model, particularly in males⁽¹¹⁶⁾. This has promoted
 456 interest in probiotics for ameliorating both gut and behavioural
 457 symptoms^(117,118). FMT has also been shown to change brain
 458 chemistry and behaviour in germ-free recipient mice⁽¹¹⁹⁾.
 459 One outcome from transplanting from mice on a high-fat diet to
 460 those on normal feed was a negative change in neurocognitive
 461 behaviour⁽¹²⁰⁾.

462 IBS is considered a disorder of the gut–brain axis, and
 463 microbiome research confirms this. Transient dysbiosis early in
 464 life affects visceral sensitivity, increasing the risk for later
 465 developing IBS⁽¹²¹⁾. The gut microbiota profile also correlates
 466 with the clinical phenotype of patients⁽¹²²⁾. Probiotic benefit has
 467 been demonstrated in several animal studies⁽¹²³⁾, and human
 468 study evidence is accumulating, particularly with lactic acid
 469 bacteria⁽¹²⁴⁾. IBS patients also appear to have a subtle deficit in
 470 cognitive behaviour linked to changes in cortisol levels; perhaps
 471 this is another target for probiotics⁽¹²⁵⁾.

472 Finally, Professor Cryan introduced the term ‘psychobiotics’
 473 for probiotics aimed at psychiatric illness⁽¹²⁶⁾. Since a first report
 474 in 1910⁽¹²⁷⁾, data are now accumulating on improvements in
 475 mental health parameters associated with lactobacilli and
 476 bifidobacteria^(128–131).

477 *Prostate cancer*

478 Professor Hideyuki Akaza (The University of Tokyo, Japan)
 479 began by outlining the geographical differences in prostate
 480 cancer (PC) incidence. Although PC is much lower in Asian
 481 countries compared with Western countries⁽¹³²⁾, Japanese
 482 migrants in Hawaii have an increased PC incidence compared
 483 with Japanese people still living in Japan. This observation
 484 suggested that lifestyle factors, and not just diet, may be involved
 485 in determining disease risk⁽¹³³⁾. As this cancer progresses very
 486 slowly (up to 27 years), preventive interventions are worth
 487 pursuing⁽¹³⁴⁾. It may not be cost-effective or even safe for drugs
 488 such as 5 α -reductase inhibitors⁽¹³⁵⁾ to be taken over long periods,
 489 making dietary interventions a better option.

490 In 1998, a detailed examination of UN data for fifty-nine
 491 countries on PC-related mortality, dietary intake and lifestyle
 492 factors highlighted the particular benefit of soya consumption in
 493 protecting against the disease⁽¹³⁶⁾, a finding confirmed by later
 494 meta-analysis⁽¹³⁷⁾. The active ingredients in soya are isoflavones,
 495 such as genistein, daidzein and equol⁽¹³⁸⁾. The anti-androgen
 496 activity of equol is explained by its ability to bind to oestrogen
 497 receptor β and the sex hormone-binding globulin (SHBG), thus
 498 inhibiting the growth of sex hormone-dependent tumours such
 499 as PC⁽¹³⁹⁾.

500 Certain bacterial species in the colon are able to metabolise
 501 daidzen to produce equol, but these species are only carried by
 502 about 30 % of people consuming a Western diet, which is low in
 503 soya⁽¹⁴⁰⁾. Professor Akaza’s group conducted a study on healthy
 504 Japanese people (both equol producers and non-producers),
 505 given 60 mg soya isoflavones daily for 3 months, which caused
 506 an increase in serum levels of equol and SHBG and a decrease
 507 in free testosterone and dihydrotestosterone⁽¹⁴¹⁾. The results also
 508 indicated that prolonged consumption of soya isoflavone might
 509 convert non-equol producers to equol producers; this may be
 510 an important finding as the lack of ability to metabolise daidzein

to equol in the colon appears to be a PC risk factor⁽¹⁴²⁾. Numbers of equol producers are low in Western countries, where PC risk is higher compared with countries such as Japan and Korea. Worryingly, the ability to produce equol appears to be dropping in the Japanese population, which could be linked to a parallel rise in PC incidence⁽¹⁴³⁾. A phase II placebo-controlled pilot trial in men with rising prostate-specific antigen showed that dietary supplementation of isoflavone for 12 months significantly increased serum levels of equol in subjects known to produce this metabolite. In subjects aged 65 years or older, the incidence of PC was also lower in the test group compared with the placebo group⁽¹⁴⁴⁾.

A novel *Slackia* spp. strain NATTS – a gram-positive bacterium belonging to the phylum Actinobacteria and isolated from Japanese adults – can produce high levels of equol⁽¹⁴⁵⁾. Research is now focusing on understanding the global distribution of equol-producing strains and comparing this with PC risk. Large-scale intervention studies are also planned, which will investigate men at high risk of PC and the potential benefit of intervention with soya foods, equol supplements and/or foods containing the *Slackia* strain or its daidzein-metabolising enzymes. The realisation of a link between components of the intestinal microbiota and cancer risk reduction will support the development of a new research field⁽¹⁴⁶⁾.

Antibiotic-associated diarrhoea in spinal cord injury patients

People with spinal cord injury (SCI) face a range of health problems, explained Dr Samford Wong (Stoke Mandeville Hospital, UK), which is why quality of life is a key research focus. Patients are encouraged to participate in sport and supported into re-employment but complications, such as malnutrition, affect clinical outcome⁽¹⁴⁷⁾. Use of catheters increases risk of urinary tract infection as well as diarrhoea resulting from antibiotic treatment delays rehabilitation, which affects the patient and increases their health-care costs. This is why cost-effective, reliable and simple measures are needed. Probiotics have potential for preventing AAD⁽¹⁴⁸⁾ and in fact are already being used in some SCI centres. However, medical staff are not always aware that efficacy can be strain-, dose- and disease-specific.

Recently an RCT in SCI patients conducted by Dr Wong demonstrated that a fermented milk drink containing *L. casei* Shirota significantly prevented AAD, which developed in 54.9% of patients in the control group compared with 17.1% given the probiotic⁽¹⁴⁹⁾. To fully evaluate probiotic potential for SCI patients, Dr Wong proposed a three-step approach: (i) to evaluate current AAD and *C. difficile*-AD (CDAD) practices in UK and European SCI centres; (ii) to conduct a systematic review and meta-analysis on their effectiveness in preventing AAD/CDAD in SCI patients; and (iii) to conduct a multicentre, double-blind, placebo-controlled trial to confirm the benefit of *L. casei* Shirota.

HIV

HIV/AIDS is characterised by a progressive depletion of CD4+ T-cells and a severe impairment of the immune system. This is often accompanied by an alteration of the gut mucosal barrier,

which allows translocation of microbes and their products, and provokes a chronic state of inflammation⁽¹⁵⁰⁾. In view of the immunomodulatory effects reported for probiotics in non-immunocompetent and HIV+ subjects^(151,152), Dr D'Angelo's ('G. d'Annunzio' University of Chieti-Pescara, Italy) group conducted a pilot study on the effects of *L. casei* Shirota (at 1.3×10^{10} CFU/d for 4 weeks) on clinically stable HIV+ patients on antiretroviral therapy⁽¹⁵³⁾. Blood samples were taken before and after the intervention. Haematological (lymphocyte subsets), immunological (circulating cytokine levels and mRNA expression in peripheral blood mononuclear cells) and other parameters (LPS and cystatin C) were measured. The probiotic was associated with slightly reduced plasma LPS, significantly increased CD56+ and significantly reduced mRNA levels of IL-1 β , IL-10, IL-12 and transforming growth factor- β in peripheral blood mononuclear cells, while plasma IL-23 increased. An observed decrease of cystatin C also indicated that cardiovascular risk might be reduced. Dr D'Angelo concluded that this preliminary evidence of an improvement in systemic inflammatory cytokines suggests that this probiotic could improve the management of antiretroviral therapy-treated HIV+ patients and warrants further investigation.

Probiotic mechanisms: immune modulation and effects of metabolites

Faecalibacterium prausnitzii

This bacterium, the subject of a talk by Professor Philippe Langella (INRA, France), is an ubiquitous commensal species comprising >3.5% of the gut microbiota, which is extremely oxygen sensitive and a butyrate producer. It belongs to the gram-positive Firmicutes phylum and *Clostridium leptum* group cluster IV⁽¹⁵⁴⁻¹⁵⁶⁾. Reduced abundance and diversity of Firmicutes occur in CD patients. A landmark study by Sokol *et al.*⁽¹⁵⁷⁾ in 2008 also demonstrated an association between reduced *F. prausnitzii* numbers and increased risk for postoperative recurrence of ileal CD. The species was also shown to have anti-inflammatory effects in cellular and animal models of gut inflammation⁽¹⁵⁷⁾. A different strategy to find new probiotic strains was proposed: identify candidate species whose presence/absence is linked to health in diseases linked to microbial dysbiosis. One such species is *F. prausnitzii*. Having been linked to dysbiosis in CD, UC, colorectal cancer and IBS, it could almost be an indicator of intestinal health⁽¹⁵⁸⁻¹⁶⁰⁾. A novel, chronic dinitrobenzene sulphonic acid (DNBS)-induced acute and chronic colitis model in mice developed by Professor Langella's group showed that *F. prausnitzii* and its supernatant protected the gut epithelium during episodes of chronic colitis and its reactivation⁽¹⁶¹⁾.

The same DNBS-induced mouse model was adapted to better mimic IBS, with cycles of low-grade, sub-clinical inflammation and then a period of recovery followed by reactivation of inflammation. The IBS mice had raised levels of serotonin and inflammatory cytokines in the colon (IL-6, interferon- γ (IFN- γ), IL-4 and IL-22), as well as impaired gut permeability, but these effects were reversed following treatment with *F. prausnitzii* or its supernatant⁽¹⁶²⁾. The species was also tested in a neonatal

maternal separation model that induces colonic hypersensitivity and increases gut permeability. In this pain model, *F. prausnitzii* strain A2–165 (now patented) demonstrated antinociceptive effects and restored gut permeability.

A further *F. prausnitzii* gnotobiotic model has been developed, where dual colonisation with *E. coli* achieves more effective and stable colonisation by *F. prausnitzii*. When colitis was induced in this model, disease activity and other parameters were improved by the presence of *F. prausnitzii*. The species was also shown to be very metabolically active, producing several compounds with beneficial effects, such as shikimic and salicylic acids. Both have anti-pain activity; the latter is also a precursor of 5-aminosalicylic acid, the anti-inflammatory drug used to treat IBD⁽¹⁶³⁾.

The next stage is to develop *F. prausnitzii* as a human probiotic, but first a few obstacles have to be overcome. The species is considered to be a novel food; hence, full toxicology assays and characterisation of the strain are needed for regulatory approval. The freeze-drying process for commercial preparation of the strain also needs to be optimised. Work is continuing to fully understand the species, its mode of action and its bioactive metabolites.

Immunomodulatory mechanisms of probiotics

Dr Liam O'Mahony (Swiss Institute of Allergy and Asthma Research, Switzerland) explained that immune tolerance in the gut evolved in order to minimise the impact on the host of dealing with an invader and to allow the commensal microbiota to colonise the gut, where it provides nutrients to and protection for the host^(164,165). In conditions of gut dysbiosis, however, even commensal bacteria can trigger an inappropriate inflammatory response⁽¹⁶⁶⁾. For example, recognition of segmented filamentous bacteria by the mucosal immune system can, in the wrong circumstances, lead to T-helper 17 cell-mediated inflammation⁽¹⁶⁷⁾. Gut microbiota colonisation in early-life influences the risk for immune disorders; allergy development in germ-free mice, for instance, depends on what age the mice are colonised with bacteria⁽¹⁶⁸⁾. Mice studies show that food allergy is associated with a particular profile of gut microbiota; this triggered allergy and anaphylaxis when transplanted to germ-free mice⁽¹⁶⁹⁾.

Dr O'Mahony's group is elucidating the cellular and molecular effects of an immunoregulatory probiotic, *B. longum* subsp. *infantis* 35624⁽¹⁷⁰⁾. In mice, its consumption resulted in induction of T-regulatory cells and attenuation of NF- κ B activation, preventing excessive inflammation induced by *Salmonella* infection⁽¹⁷¹⁾. Induction of T-regulatory cells by the strain has also been shown in humans, as well as reduction of systemic pro-inflammatory biomarkers in patients with psoriasis, IBS, chronic fatigue syndrome or UC⁽¹⁷²⁾. In the peripheral blood, the strain stimulates dendritic cell-induced T-regulatory cells to produce IL-10 and also enhances *Foxp3* expression. It also reduces production of IL-12 and TNF- α , effects which all appear to be strain-specific^(173,174).

Bacterial metabolites can also exert immunological effects. The biogenic amine histamine, which is found at particularly high levels in the gut mucosa of IBS and IBD patients, can promote either pro- or anti-inflammatory effects depending

on which of its four receptors are activated^(175,176). Not all commensal bacteria, however, express histidine decarboxylase (the enzyme needed to convert histidine to histamine). The isolate *Lactobacillus saerimneri* strain 30a produces high levels of biologically active histamine⁽¹⁷⁷⁾. Feeding this strain to wild-type mice and mice lacking histamine receptor 2, for example, resulted in a deterioration in health. Current research is investigating the ability of the gut microbiota to produce histamine, as this may have health implications.

SCFA are other types of bacterial metabolites with immunoregulatory effects. Dr O'Mahony's group has used an ovalbumin-challenge respiratory allergy model to show that butyrate reduces pro-inflammatory cytokines such as IL-17, which can be raised with asthma. Dr O'Mahony stressed that the timing of any intervention relating to immune benefit may be critical; the greatest effects are likely to be early in life⁽¹⁷⁸⁾.

Campylobacter infection

Although *Campylobacter* is the most common bacterial cause of enteritis in industrialised countries, Professor Stefan Bereswill (Charité – University Medicine Berlin, Germany) explained that its pathogenicity is still not fully understood. Although *Campylobacter jejuni* can asymptotically colonise animals such as chickens and cows, it causes inflammation and acute diarrhoea in humans, and rare but serious post-infectious immune-related disorders such as Guillain-Barré syndrome⁽¹⁷⁹⁾. Mice with a normal gut microbiota display a strong colonisation resistance to *C. jejuni*; hence, finding a good animal model for this infection has proved a challenge for researchers. Wild-type and GM mice models have now been developed, where the commensal microbiota has been eradicated or modified (e.g. to one resembling a human gut microbiota)⁽¹⁸⁰⁾. Infant mice harbouring a conventional gut microbiota have much higher counts of commensal *E. coli* compared with adult animals, and overgrowth of the murine gut microbiota with *E. coli* abrogates colonisation resistance against *C. jejuni*^(181,182). The pathogen readily colonises antibiotic-treated gnotobiotic mice with a knockout for IL-10 expression (i.e. IL-10^{-/-}), causing enterocolitis and the development of LPS-mediated inflammation and specific T-cell responses that are characteristic of campylobacteriosis in humans^(180,183). Studies on these mice have shown that *C. jejuni* is a potent activator of the innate immune response via toll-like receptor (TLR) 4 and, to a lesser extent, TLR2 (these receptors detect LPS and lipoprotein molecules on the bacterial surface). TLR4 and TLR2 also appear to be involved in the ability of the pathogen to induce inflammation and apoptosis of enterocytes⁽¹⁸⁴⁾. The addition of a sialic acid derivative to the surface LPS of *C. jejuni* also aggravates its interaction with TLR, increasing the invasion, translocation and inflammatory potential of the pathogen and thereby raising the risk of post-infectious complications⁽¹⁸⁵⁾. Several cytokines have been identified as important in protection against *Campylobacter*. Investigations using human biopsy material, for example, have shown that the innate and adaptive T-cell immune responses to *C. jejuni* are associated with production of IFN- γ , IL-22 and IL-17A⁽¹⁸⁶⁾. The Gastrointestinal Microbiology Research Group at Charité (headed by Markus Heimesaat and

Stefan Bereswill) has shown that IL-22 and IL-23 are essential for maintaining the composition of the intestinal microbiota; this then helps maintain colonisation resistance. Current work is aimed at analysing the pro- and anti-inflammatory T-cell subsets in murine infections and in IL-22^{-/-} and IL-23^{-/-} mice. *C. jejuni* infection in 3-week-old mice results in a self-limiting illness, but neutrophil infiltration can be observed in the colon, liver, lungs and kidneys, and this can lead to a state of chronic inflammation in asymptomatic carriers. The similarity of this pathology to the human disease with its serious postoperative complications means that these novel animal models will be extremely useful tools for *C. jejuni* research and perhaps development of probiotics to help prevent this infection.

Butyric acid, the oral microbiota and ageing

A complex association exists between periodontal disease and certain systemic disorders such as arteriosclerosis, T2D, pneumonia, heart disease and premature childbirth^(187–189). Professor Kuniyasu Ochiai's (Nihon University School of Dentistry, Japan) group are researching into this, focusing on the role of butyric acid (BA), which is produced at high levels by periodontopathic plaque species such as *Porphyromonas gingivalis*, *Fusobacterium nucleatum* and *Eubacterium*^(190,191). BA accumulates in gingival crevices at higher levels in periodontitis cases compared with the healthy⁽¹⁹⁰⁾ and could serve as a promoter of periodontitis^(192,193). At low concentrations, BA stimulates cell growth, but at higher concentrations it induces apoptosis in neutrophils, T-cells and macrophages^(191,194,195). T-cells survive by adhering to fibroblasts⁽¹⁹⁶⁾ as a result of increased expression of adhesion molecules plus increased production of pro-inflammatory cytokines IL-6 and IL-11 by the gingival fibroblasts. Although fibroblasts are usually resistant to BA-induced apoptosis, cells from periodontitis patients are highly sensitive⁽¹⁹⁷⁾.

The complex signalling network associated with oral BA shows how it may elicit systemic effects, which could influence ageing and latent infections. Animal studies have shown that BA-induced primary signalling affects total haem, NADP and hydrogen peroxide⁽¹⁹⁸⁾. These compounds are linked to the free radical theory of ageing⁽¹⁹⁹⁾, reactivation of latent infections such as HIV⁽²⁰⁰⁾, periodontal disease⁽²⁰¹⁾ and promotion of *P. gingivalis*⁽²⁰²⁾. Secondary signalling affects cytosolic and serum levels of Ca (factors associated with osteoporosis and Alzheimer's disease)^(203,204) and caspases (proteases important for apoptosis and inflammation)⁽²⁰⁵⁾. The late network caused by BA affects the oxidised form of NAD, sirtuin1 and the mammalian target of rapamycin, and is linked to the ageing processes^(198,199).

In HIV-infected patients, degree of periodontitis correlates to HIV-RNA load in gingival crevicular fluid⁽²⁰⁶⁾. Professor Ochiai's group found that the BA produced by *P. gingivalis* acts as an epigenetic regulator, inhibiting the histone deacetylases that maintain HIV latency⁽²⁰⁷⁾. Severe periodontitis could trigger a synergy between the local effects of BA in gingival tissue and systemic effects of induced TNF- α . An epidemiological study has started in Japan to confirm whether periodontal disease is a risk factor for HIV reactivation. Epstein-Barr virus (EBV), another latent infection, has been isolated from patients with

periodontitis^(208,209), and BA in *P. gingivalis* culture supernatant can also reactivate EBV *in vitro* by a mechanism involving histone modification and chromatin remodelling⁽²¹⁰⁾.

These findings show BA in a new light. Although it is considered beneficial in the gut, Professor Ochiai debated whether we need to understand the effects of high levels of SCFA on gut tissues. His final message was very clear: brush your teeth!

A re-examination of the probiotic definition and category

'Probiotic' means different things to different people depending on their particular interest, explained Professor Colin Hill (University College Cork, Ireland). Some health conditions (e.g. AAD) respond to several different probiotics⁽⁵⁰⁾, yet some probiotics are associated with several health benefits⁽²¹¹⁾, and a further complication is that some effects are very strain-specific⁽²¹²⁾. In response to concerns about regulatory developments in Europe as well as misuse of the term 'probiotic' and confusion of general public about this category, the International Scientific Association for Probiotics and Prebiotics organised a meeting in 2013 to re-examine the probiotic concept. The panel comprised clinical and scientific experts, including members of an original FAO/WHO expert panel, who in 2001 had agreed what has been a widely accepted definition for probiotics⁽²¹³⁾. Professor Hill gave an insight into these discussions and the resulting consensus statement, published in 2014⁽²¹⁴⁾.

The panel endorsed the 2001 probiotic definition, with just a small change to improve its grammar to: 'Live micro-organisms that, when administered in adequate amounts, confer a health benefit on the host'. They recommended that 'probiotic' should only apply to products containing a suitable number of live cells of well-defined and safe microbial strains and with a reasonable level of scientific evidence of health benefit from a body of research that included well-conducted human studies. The panel agreed that the process of assessment of scientific evidence for food probiotics should differ from the assessment for pharmaceutical drugs, and the process should be consistent with other foods that have approved health claims (e.g. vitamins). The panel agreed that changes are needed by regulators in jurisdictions such as the USA and Europe⁽²¹⁵⁾.

The panel identified three categories of probiotics:

- Microbial species, used in a food or food supplement, without a specific health claim
 - with reasonable evidence of a general benefit for humans associated with the species itself and/or its function, structure, activity or end product;
 - claim: 'contains probiotics'.
- Microbial strains, used in/as a food or food supplement, with a specific health claim
 - based on convincing evidence specific to the constituent strain(s) to satisfy the appropriate regulatory authority.
- Microbial strains, used as probiotic drugs
 - sufficient trial evidence to meet appropriate regulatory standards for drugs.

A very broad range of bacterial species have been associated with a robust gut microbiota; therefore, it is very likely that the

probiotic framework could be extended to include new well-defined beneficial microbes, such as *A. muciniphila* and *F. prausnitzii*, but this could only happen when/if there is sufficient evidence of the benefit and understanding of mechanism of activity.

Dead microbes or microbial products are not probiotic. Live microbial cultures with no evidence of benefit that are traditionally associated with fermented foods also fall outside the probiotic framework and should be labelled as 'containing live and active cultures'. FMT cannot be considered probiotic, because this involves an undefined mixture of micro-organisms. FMT preparations containing defined mixtures of microbes, such as RePOOPulate, however, do meet the probiotic criteria⁽²¹⁶⁾.

The panel supported the concept that certain well-studied species could impart general benefits, particularly for gut health but not for immune health. This has been concluded in meta-analyses⁽²¹⁷⁾ and acknowledged in Canada where non-strain-specific claims are allowed for various species of *Lactobacillus* and *Bifidobacterium*⁽²¹⁸⁾. There were more tentative conclusions regarding mechanisms of activity: some (such as colonisation resistance and SCFA production) were considered to be widespread among studied probiotics; others were considered to occur frequently within the same species (such as vitamin synthesis and gut barrier reinforcement); and others were considered to be rare and strain-specific (such as neurological and immunological effects).

The consensus statement is valuable in providing clear guidelines for all stakeholders in the probiotics sector, be they researchers, regulators, health-care professionals, manufacturers or consumers.

Acknowledgements

The 8th International Yakult Symposium was financially supported by Yakult Europe B.V., Almere, The Netherlands. The present report was commissioned by Yakult Europe B.V.

L. V. T., K. S. and J. Z. contributed to the writing of the report. None of the authors has any conflicts of interest to declare.

Publication of this supplement was supported by an educational grant from Yakult Europe BV. This review has undergone the standard review process and may be cited.

References

- El Aidy S, van den Bogert B & Kleerebezem M (2015) The small intestine microbiota, nutritional modulation and relevance for health. *Curr Opin Biotechnol* **32**, 14–20.
- van der Schaar PJ, Dijkman JF, Broekhuizen-de Gast H, *et al.* (2013) A novel ingestible electronic drug delivery and monitoring device. *Gastrointest Endosc* **78**, 520–528.
- Rajilic-Stojanovic M, Heilig HG, Molenaar D, *et al.* (2009) Development and application of the human intestinal tract chip, a phylogenetic microarray: analysis of universally conserved phylotypes in the abundant microbiota of young and elderly adults. *Environ Microbiol* **11**, 1736–1751.
- Booijink CC, El-Aidy S, Rajilic-Stojanovic M, *et al.* (2010) High temporal and inter-individual variation detected in the human ileal microbiota. *Environ Microbiol* **12**, 3213–3227.
- van den Bogert B, de Vos WM, Zoetendal EG, *et al.* (2011) Microarray analysis and barcoded pyrosequencing provide consistent microbial profiles depending on the source of human intestinal samples. *Appl Environ Microbiol* **77**, 2071–2080.
- Zoetendal EG, Raes J, van den Bogert B, *et al.* (2012) The human small intestinal microbiota is driven by rapid uptake and conversion of simple carbohydrates. *ISME J* **6**, 1415–1426.
- van den Bogert B, Erkus O, Boekhorst J, *et al.* (2013) Diversity of human small intestinal *Streptococcus* and *Veillonella* populations. *FEMS Microbiol Ecol* **85**, 376–388.
- van Baarlen P, Troost F, van der Meer C, *et al.* (2011) Human mucosal *in vivo* transcriptome responses to three lactobacilli indicate how probiotics may modulate human cellular pathways. *Proc Natl Acad Sci U S A* **108**, Suppl. 1, 4562–4569.
- van Baarlen P, Troost FJ, van Hemert S, *et al.* (2009) Differential NF-kappaB pathways induction by *Lactobacillus plantarum* in the duodenum of healthy humans correlating with immune tolerance. *Proc Natl Acad Sci U S A* **106**, 2371–2376.
- Yan F, Cao H, Cover TL, *et al.* (2007) Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. *Gastroenterology* **132**, 562–575.
- Lamb J (2007) The connectivity map: a new tool for biomedical research. *Nat Rev Cancer* **7**, 54–60.
- Bron PA, van Baarlen P & Kleerebezem M (2012) Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa. *Nat Rev Microbiol* **10**, 66–78.
- Hedin CR, Stagg AJ, Whelan K, *et al.* (2012) Family studies in Crohn's disease: new horizons in understanding disease pathogenesis, risk and prevention. *Gut* **61**, 311–318.
- Frank DN, St Amand AL, Feldman RA, *et al.* (2007) Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. *Proc Natl Acad Sci U S A* **104**, 13780–13785.
- Lepage P, Hasler R, Spehlmann ME, *et al.* (2011) Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. *Gastroenterology* **141**, 227–236.
- Renz H, von Mutius E, Brandtzaeg P, *et al.* (2011) Gene-environment interactions in chronic inflammatory disease. *Nat Immunol* **12**, 273–277.
- Hilsden RJ, Verhoef MJ, Rasmussen H, *et al.* (2011) Use of complementary and alternative medicine by patients with inflammatory bowel disease. *Inflamm Bowel Dis* **17**, 655–662.
- Fernandez-Banares F, Hinojosa J, Sanchez-Lombrana JL, *et al.* (1999) Randomized clinical trial of *Plantago ovata* seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). *Am J Gastroenterol* **94**, 427–433.
- Fujimori S, Tatsuguchi A, Gudis K, *et al.* (2007) High dose probiotic and prebiotic cotherapy for remission induction of active Crohn's disease. *J Gastroenterol Hepatol* **22**, 1199–1204.
- Langhorst J, Wulfert H, Lauche R, *et al.* (2015) Systematic review of complementary and alternative medicine treatments in inflammatory bowel diseases. *J Crohns Colitis* **9**, 86–106.
- Dignass A, Preiss JC, Aust DE, *et al.* (2011) [Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011]. *Z Gastroenterol* **49**, 1276–1341.
- Storr M, Devlin S, Kaplan GG, *et al.* (2014) Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn's disease. *Inflamm Bowel Dis* **20**, 472–480.

- 963 23. Joos S, Wildau N, Kohnen R, *et al.* (2006) Acupuncture and
964 moxibustion in the treatment of ulcerative colitis: a randomized
965 controlled study. *Scand J Gastroenterol* **41**, 1056–1063.
966 24. Rogler G & Vavricka S (2015) Exposome in IBD: recent
967 insights in environmental factors that influence the onset and
968 course of IBD. *Inflamm Bowel Dis* **21**, 400–408.
969 25. Clarke SF, Murphy EF, O'Sullivan O, *et al.* (2014) Exercise
970 and associated dietary extremes impact on gut microbial
971 diversity. *Gut* **63**, 1913–1920.
972 26. Cosnes J (2010) Smoking, physical activity, nutrition and
973 lifestyle: environmental factors and their impact on IBD. *Dig
974 Dis* **28**, 411–417.
975 27. Levenstein S, Prantera C, Varvo V, *et al.* (2000) Stress and
976 exacerbation in ulcerative colitis: a prospective study of patients
977 enrolled in remission. *Am J Gastroenterol* **95**, 1213–1220.
978 28. Bernstein CN, Singh S, Graff LA, *et al.* (2010) A prospective
979 population-based study of triggers of symptomatic flares in
980 IBD. *Am J Gastroenterol* **105**, 1994–2002.
981 29. Jedel S, Hoffman A, Merriman P, *et al.* (2014) A randomized
982 controlled trial of mindfulness-based stress reduction to
983 prevent flare-up in patients with inactive ulcerative colitis.
984 *Digestion* **89**, 142–155.
985 30. Berrill JW, Sadlier M, Hood K, *et al.* (2014) Mindfulness-
986 based therapy for inflammatory bowel disease patients with
987 functional abdominal symptoms or high perceived
988 stress levels. *J Crohns Colitis* **8**, 945–955.
989 31. Bailey MT, Dowd SE, Galley JD, *et al.* (2011) Exposure to a
990 social stressor alters the structure of the intestinal microbiota:
991 implications for stressor-induced immunomodulation. *Brain
992 Behav Immun* **25**, 397–407.
993 32. van Nood E, Vrieze A, Nieuwdorp M, *et al.* (2013) Duodenal
994 infusion of donor feces for recurrent *Clostridium difficile*.
995 *N Engl J Med* **368**, 407–415.
996 33. Kao D, Hotte N, Gillevet P, *et al.* (2014) Fecal microbiota
997 transplantation inducing remission in Crohn's colitis and the
998 associated changes in fecal microbial profile. *J Clin Gastro-
999 enterol* **48**, 625–628.
1000 34. Kump PK, Grochenig HP, Lackner S, *et al.* (2013) Alteration
1001 of intestinal dysbiosis by fecal microbiota transplantation
1002 does not induce remission in patients with chronic active
1003 ulcerative colitis. *Inflamm Bowel Dis* **19**, 2155–2165.
1004 35. Moayyedi P, Surette MG, Kim PT, *et al.* (2015) Fecal
1005 microbiota transplantation induces remission in patients with
1006 active ulcerative colitis in a randomized, controlled trial.
1007 *Gastroenterology* **149**, 102–109.
1008 36. Rossen NG, Fuentes S, van der Spek MJ, *et al.* (2015) Findings
1009 from a randomized controlled trial of fecal transplantation for
1010 patients with ulcerative colitis. *Gastroenterology* **149**, 110–118.
1011 37. Jones J & Hunter D (1995) Consensus methods for medical
1012 and health services research. *BMJ* **311**, 376–380.
1013 38. Guyatt GH, Oxman AD, Schunemann HJ, *et al.* (2011)
1014 GRADE guidelines: a new series of articles in the Journal of
1015 Clinical Epidemiology. *J Clin Epidemiol* **64**, 380–382.
1016 39. O'Mahony L, McCarthy J, Kelly P, *et al.* (2005) *Lactobacillus*
1017 and *Bifidobacterium* in irritable bowel syndrome: symptom
1018 responses and relationship to cytokine profiles. *Gastro-
1019 enterology* **128**, 541–551.
1020 40. Whorwell PJ, Altringer L, Morel J, *et al.* (2006) Efficacy of an
1021 encapsulated probiotic *Bifidobacterium infantis* 35624 in
1022 women with irritable bowel syndrome. *Am J Gastroenterol*
1023 **101**, 1581–1590.
1024 41. McFarland LV & Dublin S (2008) Meta-analysis of probiotics
1025 for the treatment of irritable bowel syndrome. *World J
1026 Gastroenterol* **14**, 2650–2661.
1027 42. Ford AC, Quigley EM, Lacy BE, *et al.* (2014) Efficacy of
1028 prebiotics, probiotics, and synbiotics in irritable bowel
1029 syndrome and chronic idiopathic constipation: systematic
1030 review and meta-analysis. *Am J Gastroenterol* **109**, 1547–1561
1031 quiz 1546, 1562.
1032 43. Chang L, Lembo A & Sultan S (2014) American Gastro-
1033 enterological Association Institute Technical Review on the
1034 pharmacological management of irritable bowel syndrome.
1035 *Gastroenterology* **147**, 1149–1172.
1036 44. National Institute for Health and Care Excellence (2015)
1037 Irritable bowel syndrome in adults: diagnosis and manage-
1038 ment of irritable bowel syndrome in primary care. NICE
1039 Guidelines CG61. [https://www.nice.org.uk/guidance/cg61/
1040 chapter/1-guidance](https://www.nice.org.uk/guidance/cg61/chapter/1-guidance) (accessed August 2015).
1041 45. Layer P, Andresen V, Pehl C, *et al.* (2011) [Irritable bowel
1042 syndrome: German consensus guidelines on definition,
1043 pathophysiology and management]. *Z Gastroenterol* **49**,
1044 237–293.
1045 46. Szajewska H, Guarino A, Hojsak I, *et al.* (2014) Use of
1046 probiotics for management of acute gastroenteritis: a position
1047 paper by the ESPGHAN Working Group for Probiotics and
1048 Prebiotics. *J Pediatr Gastroenterol Nutr* **58**, 531–539.
1049 47. Saavedra JM, Bauman NA, Oung I, *et al.* (1994) Feeding of
1050 *Bifidobacterium bifidum* and *Streptococcus thermophilus* to
1051 infants in hospital for prevention of diarrhoea and shedding
1052 of rotavirus. *Lancet* **344**, 1046–1049.
1053 48. Szajewska H, Wanke M & Patro B (2011) Meta-analysis: the
1054 effects of *Lactobacillus rhamnosus* GG supplementation for
1055 the prevention of healthcare-associated diarrhoea in children.
1056 *Aliment Pharmacol Ther* **34**, 1079–1087.
1057 49. Hojsak I, Tokic Pivac V, Mocić Pavić A, *et al.* (2015)
1058 *Bifidobacterium animalis* subsp. *lactis* fails to prevent common
1059 infections in hospitalized children: a randomized, double-blind,
1060 placebo-controlled study. *Am J Clin Nutr* **101**, 680–684.
1061 50. Hempel S, Newberry SJ, Maher AR, *et al.* (2012) Probiotics
1062 for the prevention and treatment of antibiotic-associated
1063 diarrhea: a systematic review and meta-analysis. *JAMA* **307**,
1064 1959–1969.
1065 51. AlFaleh K & Anabrees J (2014) Probiotics for prevention of
1066 necrotizing enterocolitis in preterm infants. *Evid Based Child
1067 Health* **9**, 584–671.
1068 52. Chau K, Lau E, Greenberg S, *et al.* (2015) Probiotics for
1069 infantile colic: a randomized, double-blind, placebo-controlled
1070 trial investigating *Lactobacillus reuteri* DSM 17938. *J Pediatr*
1071 **166**, 74–78.
1072 53. Mi GL, Zhao L, Qiao DD, *et al.* (2015) Effectiveness of
1073 *Lactobacillus reuteri* in infantile colic and colicky induced
1074 maternal depression: a prospective single blind randomized
1075 trial. *Antonie Van Leeuwenhoek* **107**, 1547–1553.
1076 54. Sung V, Hiscock H, Tang ML, *et al.* (2014) Treating
1077 infant colic with the probiotic *Lactobacillus reuteri*: double
1078 blind, placebo controlled randomised trial. *BMJ* **348**,
1079 g2107.
1080 55. Urbanska M & Szajewska H (2014) The efficacy of
1081 *Lactobacillus reuteri* DSM 17938 in infants and children: a
1082 review of the current evidence. *Eur J Pediatr* **173**, 1327–1337.
1083 56. Indrio F, Di Mauro A, Riezzo G, *et al.* (2014) Prophylactic use
1084 of a probiotic in the prevention of colic, regurgitation, and
1085 functional constipation: a randomized clinical trial. *JAMA
1086 Pediatr* **168**, 228–233.
1087 57. Fiocchi A, Pawankar R, Cuello-Garcia C, *et al.* (2015) World
1088 Allergy Organization-McMaster University guidelines for
1089 allergic disease prevention (GLAD-P): probiotics. *World
1090 Allergy Organ J* **8**, 4.
1091 58. Aljada A, Mohanty P, Ghanim H, *et al.* (2004) Increase in
1092 intranuclear nuclear factor kappaB and decrease in inhibitor
1093 kappaB in mononuclear cells after a mixed meal: evidence
1094 for a proinflammatory effect. *Am J Clin Nutr* **79**, 682–690.

- 1095 59. Nappo F, Esposito K, Cioffi M, *et al.* (2002) Postprandial
1096 endothelial activation in healthy subjects and in type 2
1097 diabetic patients: role of fat and carbohydrate meals. *J Am*
1098 *Coll Cardiol* **39**, 1145–1150.
- 1099 60. Miglio C, Peluso I, Raguzzini A, *et al.* (2013) Antioxidant and
1100 inflammatory response following high-fat meal consumption
1101 in overweight subjects. *Eur J Nutr* **52**, 1107–1114.
- 1102 61. Peluso I, Raguzzini A, Villano DV, *et al.* (2012) High fat
1103 meal increase of IL-17 is prevented by ingestion of fruit juice
1104 drink in healthy overweight subjects. *Curr Pharm Des* **18**,
1105 85–90.
- 1106 62. Miglio C, Peluso I, Raguzzini A, *et al.* (2014) Fruit juice drinks
1107 prevent endogenous antioxidant response to high-fat meal
1108 ingestion. *Br J Nutr* **111**, 294–300.
- 1109 63. Peluso I, Miglio C, Morabito G, *et al.* (2015) Flavonoids and
1110 immune function in human: a systematic review. *Crit Rev*
1111 *Food Sci Nutr* **55**, 383–395.
- 1112 64. Serafini M, Bugianesi R, Maiani G, *et al.* (2003) Plasma
1113 antioxidants from chocolate. *Nature* **424**, 1013.
- 1114 65. Marin L, Miguez EM, Villar CJ, *et al.* (2015) Bioavailability
1115 of dietary polyphenols and gut microbiota metabolism:
1116 antimicrobial properties. *Biomed Res Int* **2015**, 905215.
- 1117 66. Chen Z, Zheng S, Li L, *et al.* (2014) Metabolism of flavonoids
1118 in human: a comprehensive review. *Curr Drug Metab* **15**,
1119 48–61.
- 1120 67. Nagpal R, Yadav H & Marotta F (2014) Gut microbiota: the
1121 next-gen frontier in preventive and therapeutic medicine?
1122 *Front Med (Lausanne)* **1**, 15.
- 1123 68. Ishii Y, Sugimoto S, Izawa N, *et al.* (2014) Oral administra-
1124 tion of *Bifidobacterium breve* attenuates UV-induced barrier
1125 perturbation and oxidative stress in hairless mice skin. *Arch*
1126 *Dermatol Res* **306**, 467–473.
- 1127 69. Wang AN, Yi XW, Yu HF, *et al.* (2009) Free radical
1128 scavenging activity of *Lactobacillus fermentum in vitro* and
1129 its antioxidative effect on growing-finishing pigs. *J Appl*
1130 *Microbiol* **107**, 1140–1148.
- 1131 70. Kaushal D & Kansal VK (2014) Dahi containing *Lactobacillus*
1132 *acidophilus* and *Bifidobacterium bifidum* improves phago-
1133 cytic potential of macrophages in aged mice. *J Food Sci*
1134 *Technol* **51**, 1147–1153.
- 1135 71. Kumar RS, Kanmani P, Yuvaraj N, *et al.* (2012) *Lactobacillus*
1136 *plantarum* AS1 isolated from south Indian fermented food
1137 Kallappam suppress 1,2-dimethyl hydrazine (DMH)-induced
1138 colorectal cancer in male Wistar rats. *Appl Biochem Biotechnol*
1139 **166**, 620–631.
- 1140 72. Sengul N, Isik S, Aslim B, *et al.* (2011) The effect of
1141 exopolysaccharide-producing probiotic strains on gut oxidative
1142 damage in experimental colitis. *Dig Dis Sci* **56**, 707–714.
- 1143 73. Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, *et al.* (2012)
1144 Probiotic yogurt improves antioxidant status in type 2 diabetic
1145 patients. *Nutrition* **28**, 539–543.
- 1146 74. Tilg H & Moschen AR (2014) Microbiota and diabetes: an
1147 evolving relationship. *Gut* **63**, 1513–1521.
- 1148 75. Le Chatelier E, Nielsen T, Qin J, *et al.* (2013) Richness of
1149 human gut microbiome correlates with metabolic markers.
1150 *Nature* **500**, 541–546.
- 1151 76. Cani PD, Osto M, Geurts L, *et al.* (2012) Involvement of gut
1152 microbiota in the development of low-grade inflammation
1153 and type 2 diabetes associated with obesity. *Gut Microbes* **3**,
1154 279–288.
- 1155 77. Everard A, Belzer C, Geurts L, *et al.* (2013) Cross-talk
1156 between *Akkermansia muciniphila* and intestinal epithel-
1157 ium controls diet-induced obesity. *Proc Natl Acad Sci U S A*
1158 **110**, 9066–9071.
- 1159 78. Druart C, Bindels LB, Schmaltz R, *et al.* (2015) Ability of the
1160 gut microbiota to produce PUFA-derived bacterial metabolites:
proof of concept in germ-free versus conventionalized mice. *Mol Nutr Food Res* **59**, 1603–1613.
- 1161 79. Kang JH, Yun SI & Park HO (2010) Effects of *Lactobacillus*
1162 *gasseri* BNR17 on body weight and adipose tissue mass in
1163 diet-induced overweight rats. *J Microbiol* **48**, 712–714.
- 1164 80. Karlsson CL, Molin G, Fak F, *et al.* (2011) Effects on weight
1165 gain and gut microbiota in rats given bacterial supplements
1166 and a high-energy-dense diet from fetal life through to
1167 6 months of age. *Br J Nutr* **106**, 887–895.
- 1168 81. Esposito E, Iacono A, Bianco G, *et al.* (2009) Probiotics
1169 reduce the inflammatory response induced by a high-fat diet
1170 in the liver of young rats. *J Nutr* **139**, 905–911.
- 1171 82. Chen J, Wang R, Li XF, *et al.* (2012) *Bifidobacterium*
1172 *adolescentis* supplementation ameliorates visceral fat accu-
1173 mulation and insulin sensitivity in an experimental model of
1174 the metabolic syndrome. *Br J Nutr* **107**, 1429–1434.
- 1175 83. Wang J, Tang H, Zhang C, *et al.* (2015) Modulation of gut
1176 microbiota during probiotic-mediated attenuation of metabolic
1177 syndrome in high fat diet-fed mice. *ISME J* **9**, 1–15.
- 1178 84. Kadooka Y, Sato M, Ogawa A, *et al.* (2013) Effect of *Lacto-*
1179 *bacillus gasseri* SBT2055 in fermented milk on abdominal
1180 adiposity in adults in a randomised controlled trial. *Br J Nutr*
1181 **110**, 1696–1703.
- 1182 85. Woodard GA, Encarnacion B, Downey JR, *et al.* (2009)
1183 Probiotics improve outcomes after Roux-en-Y gastric bypass
1184 surgery: a prospective randomized trial. *J Gastrointest Surg*
1185 **13**, 1198–1204.
- 1186 86. Druart C, Alligier M, Salazar N, *et al.* (2014) Modulation of
1187 the gut microbiota by nutrients with prebiotic and probiotic
1188 properties. *Adv Nutr* **5**, 624S–633S.
- 1189 87. Hulst CJ, Churnside AA & Venables MC (2015) Probiotic
1190 supplementation prevents high-fat, overfeeding-induced
1191 insulin resistance in human subjects. *Br J Nutr* **113**, 596–602.
- 1192 88. Weng H, Endo K, Li J, *et al.* (2015) Induction of peroxisomes
1193 by butyrate-producing probiotics. *PLOS ONE* **10**, e0117851.
- 1194 89. Coakley M, Ross RP, Nordgren M, *et al.* (2003) Conjugated
1195 linoleic acid biosynthesis by human-derived *Bifidobacter-*
1196 *ium* species. *J Appl Microbiol* **94**, 138–145.
- 1197 90. Everard A, Lazarevic V, Derrien M, *et al.* (2011) Responses of
1198 gut microbiota and glucose and lipid metabolism to prebiotics
1199 in genetic obese and diet-induced leptin-resistant mice.
1200 *Diabetes* **60**, 2775–2786.
- 1201 91. Everard A, Lazarevic V, Gaia N, *et al.* (2014) Microbiome of
1202 prebiotic-treated mice reveals novel targets involved in host
1203 response during obesity. *ISME J* **8**, 2116–2130.
- 1204 92. Geurts L, Neyrinck AM, Delzenne NM, *et al.* (2014) Gut
1205 microbiota controls adipose tissue expansion, gut barrier
1206 and glucose metabolism: novel insights into molecular
1207 targets and interventions using prebiotics. *Benef Microbes* **5**,
1208 3–17.
- 1209 93. Kellow NJ, Coughlan MT & Reid CM (2014) Metabolic
1210 benefits of dietary prebiotics in human subjects: a systematic
1211 review of randomised controlled trials. *Br J Nutr* **111**,
1212 1147–1161.
- 1213 94. Dewulf EM, Cani PD, Claus SP, *et al.* (2013) Insight into the
1214 prebiotic concept: lessons from an exploratory, double
1215 blind intervention study with inulin-type fructans in obese
1216 women. *Gut* **62**, 1112–1121.
- 1217 95. Salazar N, Dewulf EM, Neyrinck AM, *et al.* (2015) Inulin-type
1218 fructans modulate intestinal *Bifidobacterium* species
1219 populations and decrease fecal short-chain fatty acids in
1220 obese women. *Clin Nutr* **34**, 501–507.
- 1221 96. Druart C, Dewulf EM, Cani PD, *et al.* (2014) Gut microbial
1222 metabolites of polyunsaturated fatty acids correlate with
1223 specific fecal bacteria and serum markers of metabolic
1224 syndrome in obese women. *Lipids* **49**, 397–402.

- 1227 97. Larsen N, Vogensen FK, van den Berg FW, *et al.* (2010) Gut
1228 microbiota in human adults with type 2 diabetes differs from
1229 non-diabetic adults. *PLoS ONE* **5**, e9085. 1293
- 1230 98. Cani PD, Possemiers S, Van de Wiele T, *et al.* (2009)
1231 Changes in gut microbiota control inflammation in
1232 obese mice through a mechanism involving GLP-2-driven
1233 improvement of gut permeability. *Gut* **58**, 1091–1103. 1294
- 1234 99. El Aidy SE, Dinan TG & Cryan JF (2015) Gut microbiota: the
1235 conductor in the orchestra of immune-neuroendocrine
1236 communication. *Clin Ther* **37**, 954–967. 1295
- 1237 100. Stilling RM, Bordenstein SR, Dinan TG, *et al.* (2014) Friends
1238 with social benefits: host-microbe interactions as a driver of
1239 brain evolution and development? *Front Cell Infect Microbiol*
1240 **4**, 147. 1296
- 1241 101. Cryan JF & Dinan TG (2012) Mind-altering microorganisms:
1242 the impact of the gut microbiota on brain and behaviour. *Nat*
1243 *Rev Neurosci* **13**, 701–712. 1297
- 1244 102. O'Mahony SM, Marchesi JR, Scully P, *et al.* (2009) Early life
1245 stress alters behavior, immunity, and microbiota in rats:
1246 implications for irritable bowel syndrome and psychiatric
1247 illnesses. *Biol Psychiatry* **65**, 263–267. 1298
- 1248 103. O'Malley D, Julio-Pieper M, Gibney SM, *et al.* (2010) Distinct
1249 alterations in colonic morphology and physiology in two rat
1250 models of enhanced stress-induced anxiety and depression-
1251 like behaviour. *Stress* **13**, 114–122. 1299
- 1252 104. Borre YE, O'Keefe GW, Clarke G, *et al.* (2014) Microbiota
1253 and neurodevelopmental windows: implications for brain
1254 disorders. *Trends Mol Med* **20**, 509–518. 1300
- 1255 105. Wall R, Cryan JF, Ross RP, *et al.* (2014) Bacterial neuroactive
1256 compounds produced by psychobiotics. *Adv Exp Med Biol*
1257 **817**, 221–239. 1301
- 1258 106. Sudo N, Chida Y, Aiba Y, *et al.* (2004) Postnatal microbial
1259 colonization programs the hypothalamic-pituitary-adrenal
1260 system for stress response in mice. *J Physiol* **558**, 263–275. 1302
- 1261 107. Diaz Heijtz R, Wang S, Anuar F, *et al.* (2011) Normal gut
1262 microbiota modulates brain development and behavior. *Proc*
1263 *Natl Acad Sci U S A* **108**, 3047–3052. 1303
- 1264 108. Neufeld KM, Kang N, Bienenstock J, *et al.* (2011) Reduced
1265 anxiety-like behavior and central neurochemical change in
1266 germ-free mice. *Neurogastroenterol Motil* **23**, 255–264. 1304
- 1267 109. Clarke G, Grenham S, Scully P, *et al.* (2013) The microbiome-
1268 gut-brain axis during early life regulates the hippocampal
1269 serotonergic system in a sex-dependent manner. *Mol*
1270 *Psychiatry* **18**, 666–673. 1305
- 1271 110. Ogbonnaya ES, Clarke G, Shanahan F, *et al.* (2015) Adult
1272 hippocampal neurogenesis is regulated by the microbiome.
1273 *Biol Psychiatry* **78**, e7–e9. 1306
- 1274 111. Braniste V, Al-Asmakh M, Kowal C, *et al.* (2014) The gut
1275 microbiota influences blood-brain barrier permeability in mice.
1276 *Sci Transl Med* **6**, 263ra158. 1307
- 1277 112. Stilling RM, Dinan TG & Cryan JF (2014) Microbial genes,
1278 brain & behaviour – epigenetic regulation of the gut-brain
1279 axis. *Genes Brain Behav* **13**, 69–86. 1308
- 1280 113. Bravo JA, Forsythe P, Chew MV, *et al.* (2011) Ingestion of
1281 *Lactobacillus* strain regulates emotional behavior and central
1282 GABA receptor expression in a mouse via the vagus nerve.
1283 *Proc Natl Acad Sci U S A* **108**, 16050–16055. 1309
- 1284 114. Savignac HM, Tramullas M, Kiely B, *et al.* (2015) Bifido-
1285 bacteria modulate cognitive processes in an anxious
1286 mouse strain. *Behav Brain Res* **287**, 59–72. 1310
- 1287 115. Desbonnet L, Clarke G, Shanahan F, *et al.* (2014) Microbiota is
1288 essential for social development in the mouse. *Mol Psychiatry*
1289 **19**, 146–148. 1311
- 1290 116. de Theije CG, Wopereis H, Ramadan M, *et al.* (2014) Altered
1291 gut microbiota and activity in a murine model of autism
1292 spectrum disorders. *Brain Behav Immun* **37**, 197–206. 1312
117. Hsiao EY, McBride SW, Hsien S, *et al.* (2013) Microbiota
1293 modulate behavioral and physiological abnormalities associated
1294 with neurodevelopmental disorders. *Cell* **155**, 1451–1463. 1295
118. Gilbert JA, Krajmalnik-Brown R, Porazinska DL, *et al.* (2013)
1296 Toward effective probiotics for autism and other neuro-
1297 developmental disorders. *Cell* **155**, 1446–1448. 1298
119. Collins SM, Kassam Z & Bercik P (2013) The adoptive
1299 transfer of behavioral phenotype via the intestinal micro-
1300 biota: experimental evidence and clinical implications. *Curr*
1301 *Opin Microbiol* **16**, 240–245. 1302
120. Bruce-Keller AJ, Salbaum JM, Luo M, *et al.* (2015) Obese-type
1303 gut microbiota induce neurobehavioral changes in the
1304 absence of obesity. *Biol Psychiatry* **77**, 607–615. 1305
121. O'Mahony SM, Felice VD, Nally K, *et al.* (2014) Disturbance
1306 of the gut microbiota in early-life selectively affects visceral
1307 pain in adulthood without impacting cognitive or anxiety-
1308 related behaviors in male rats. *Neuroscience* **277**, 885–901. 1309
122. Jeffery IB, O'Toole PW, Ohman L, *et al.* (2012) An irritable
1310 bowel syndrome subtype defined by species-specific
1311 alterations in faecal microbiota. *Gut* **61**, 997–1006. 1312
123. McKernan DP, Fitzgerald P, Dinan TG, *et al.* (2010) The
1313 probiotic *Bifidobacterium infantis* 35624 displays visceral
1314 antinociceptive effects in the rat. *Neurogastroenterol Motil*
1315 **22**, 1029–1035. 1316
124. Clarke G, Cryan JF, Dinan TG, *et al.* (2012) Review article:
1317 probiotics for the treatment of irritable bowel syndrome-focus
1318 on lactic acid bacteria. *Aliment Pharmacol Ther* **35**, 403–413. 1319
125. Kennedy PJ, Clarke G, O'Neill A, *et al.* (2014) Cognitive
1320 performance in irritable bowel syndrome: evidence of a
1321 stress-related impairment in visuospatial memory. *Psychol*
1322 *Med* **44**, 1553–1566. 1323
126. Dinan TG, Stanton C & Cryan JF (2013) Psychobiotics: a
1324 novel class of psychotropic. *Biol Psychiatry* **74**, 720–726. 1325
127. Phillips JGP (1992) The treatment of melancholia by the
1326 lactic acid bacillus. *J Mental Sci* **56**, 422–431. 1327
128. Benton D, Williams C & Brown A (2007) Impact of con-
1328 suming a milk drink containing a probiotic on mood and
1329 cognition. *Eur J Clin Nutr* **61**, 355–361. 1330
129. Rao AV, Bested AC, Beaulne TM, *et al.* (2009) A randomized,
1331 double-blind, placebo-controlled pilot study of a probiotic in
1332 emotional symptoms of chronic fatigue syndrome. *Gut*
1333 *Pathog* **1**, 6. 1334
130. Steenbergen L, Sellaro R, van Hemert S, *et al.* (2015)
1335 A randomized controlled trial to test the effect of multispecies
1336 probiotics on cognitive reactivity to sad mood. *Brain Behav*
1337 *Immun* **48**, 258–264. 1338
131. Mohammadi AA, Jazayeri S, Khosravi-Darani K, *et al.* (2015)
1339 The effects of probiotics on mental health and hypothalamic-
1340 pituitary-adrenal axis: a randomized, double-blind, placebo-
1341 controlled trial in petrochemical workers. *Nutr Neurosci*
1342 (Epublication ahead of print version 16 April 2015). 1343
132. Center MM, Jemal A, Lortet-Tieulent J, *et al.* (2012) International
1344 variation in prostate cancer incidence and mortality rates. *Eur*
1345 *Urol* **61**, 1079–1092. 1346
133. Kolonel LN, Altshuler D & Henderson BE (2004) The multi-
1347 ethnic cohort study: exploring genes, lifestyle and cancer
1348 risk. *Nat Rev Cancer* **4**, 519–527. 1349
134. Cuzick J, Thorat MA, Andriole G, *et al.* (2014) Prevention and
1350 early detection of prostate cancer. *Lancet Oncol* **15**, e484–e492. 1351
135. Lacy JM & Kyprianou N (2014) A tale of two trials: the impact
1352 of 5 α -reductase inhibition on prostate cancer (review).
1353 *Oncol Lett* **8**, 1391–1396. 1354
136. Hebert JR, Hurley TG, Olenzki BC, *et al.* (1998) Nutritional
1355 and socioeconomic factors in relation to prostate cancer
1356 mortality: a cross-national study. *J Natl Cancer Inst* **90**,
1357 1637–1647. 1358

- 1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
137. Yan L & Spitznagel EL (2009) Soy consumption and prostate cancer risk in men: a revisit of a meta-analysis. *Am J Clin Nutr* **89**, 1155–1163.
138. Mahmoud AM, Yang W & Bosland MC (2014) Soy isoflavones and prostate cancer: a review of molecular mechanisms. *J Steroid Biochem Mol Biol* **140**, 116–132.
139. Lund TD, Munson DJ, Haldy ME, *et al.* (2004) Equol is a novel anti-androgen that inhibits prostate growth and hormone feedback. *Biol Reprod* **70**, 1188–1195.
140. Rafii F (2015) The role of colonic bacteria in the metabolism of the natural isoflavone daidzein to equol. *Metabolites* **5**, 56–73.
141. Tanaka M, Fujimoto K, Chihara Y, *et al.* (2009) Isoflavone supplements stimulated the production of serum equol and decreased the serum dihydrotestosterone levels in healthy male volunteers. *Prostate Cancer Prostatic Dis* **12**, 247–252.
142. Sugiyama Y, Masumori N, Fukuta F, *et al.* (2013) Influence of isoflavone intake and equol-producing intestinal flora on prostate cancer risk. *Asian Pac J Cancer Prev* **14**, 1–4.
143. Fujimoto K, Tanaka M, Hirao Y, *et al.* (2008) Age-stratified serum levels of isoflavones and proportion of equol producers in Japanese and Korean healthy men. *Prostate Cancer Prostatic Dis* **11**, 252–257.
144. Miyana N, Akaza H, Hinotsu S, *et al.* (2012) Prostate cancer chemoprevention study: an investigative randomized control study using purified isoflavones in men with rising prostate-specific antigen. *Cancer Sci* **103**, 125–130.
145. Tsuji H, Moriyama K, Nomoto K, *et al.* (2012) Identification of an enzyme system for daidzein-to-equol conversion in *Slackia* sp. strain NATTS. *Appl Environ Microbiol* **78**, 1228–1236.
146. Akaza H (2012) Prostate cancer chemoprevention by soy isoflavones: role of intestinal bacteria as the 'second human genome'. *Cancer Sci* **103**, 969–975.
147. Wong S, Derry F, Jamous A, *et al.* (2014) Is undernutrition risk associated with an adverse clinical outcome in spinal cord-injured patients admitted to a spinal centre? *Eur J Clin Nutr* **68**, 125–130.
148. Issa I & Moucari R (2014) Probiotics for antibiotic-associated diarrhea: do we have a verdict? *World J Gastroenterol* **20**, 17788–17795.
149. Wong S, Jamous A, O'Driscoll J, *et al.* (2014) A *Lactobacillus casei* Shirota probiotic drink reduces antibiotic-associated diarrhoea in patients with spinal cord injuries: a randomised controlled trial. *Br J Nutr* **111**, 672–678.
150. Brenchley JM, Price DA, Schacker TW, *et al.* (2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. *Nat Med* **12**, 1365–1371.
151. Cunningham-Rundles S, Ahrne S, Johann-Liang R, *et al.* (2011) Effect of probiotic bacteria on microbial host defense, growth, and immune function in human immunodeficiency virus type-1 infection. *Nutrients* **3**, 1042–1070.
152. Dong H, Rowland I, Thomas LV, *et al.* (2013) Immunomodulatory effects of a probiotic drink containing *Lactobacillus casei* Shirota in healthy older volunteers. *Eur J Nutr* **52**, 1853–1863.
153. D'Angelo C, Falesca K, Constantin E, *et al.* (2014) Effect of probiotic *Lactobacillus casei* Shirota on immune function of people living with HIV. IX National Conference of the Italian Society of Immunology, Clinical Immunology & Allergology. Florence, 28–31 May.
154. Miquel S, Martin R, Bridonneau C, *et al.* (2014) Ecology and metabolism of the beneficial intestinal commensal bacterium *Faecalibacterium prausnitzii*. *Gut Microbes* **5**, 146–151.
155. Miquel S, Martin R, Rossi O, *et al.* (2013) *Faecalibacterium prausnitzii* and human intestinal health. *Curr Opin Microbiol* **16**, 255–261.
156. Qin J, Li R, Raes J, *et al.* (2010) A human gut microbial gene catalogue established by metagenomic sequencing. *Nature* **464**, 59–65.
157. Sokol H, Pigneur B, Watterlot L, *et al.* (2008) *Faecalibacterium prausnitzii* is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. *Proc Natl Acad Sci USA* **105**, 16731–16736.
158. Cao Y, Shen J & Ran ZH (2014) Association between *Faecalibacterium prausnitzii* reduction and inflammatory bowel disease: a meta-analysis and systematic review of the literature. *Gastroenterol Res Pract* **2014**, 872725.
159. Balamurugan R, Rajendiran E, George S, *et al.* (2008) Real-time polymerase chain reaction quantification of specific butyrate-producing bacteria, *Desulfovibrio* and *Enterococcus faecalis* in the feces of patients with colorectal cancer. *J Gastroenterol Hepatol* **23**, 1298–1303.
160. Rajilic-Stojanovic M, Biagi E, Heilig HG, *et al.* (2011) Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. *Gastroenterology* **141**, 1792–1801.
161. Martin R, Chain F, Miquel S, *et al.* (2014) The commensal bacterium *Faecalibacterium prausnitzii* is protective in DNBS-induced chronic moderate and severe colitis models. *Inflamm Bowel Dis* **20**, 417–430.
162. Martin R, Miquel S, Chain F, *et al.* (2015) *Faecalibacterium prausnitzii* prevents physiological damages in a chronic low-grade inflammation murine model. *BMC Microbiol* **15**, 67.
163. Miquel S, Leclerc M, Martin R, *et al.* (2015) Identification of metabolic signatures linked to anti-inflammatory effects of *Faecalibacterium prausnitzii*. *MBio* **6**, e00300–e00315.
164. Read AF, Graham AL & Raberg L (2008) Animal defenses against infectious agents: is damage control more important than pathogen control. *PLoS Biol* **6**, e4.
165. Maloy KJ & Powrie F (2011) Intestinal homeostasis and its breakdown in inflammatory bowel disease. *Nature* **474**, 298–306.
166. Round JL & Mazmanian SK (2009) The gut microbiota shapes intestinal immune responses during health and disease. *Nat Rev Immunol* **9**, 313–323.
167. Atarashi K, Umesaki Y & Honda K (2011) Microbial influence on T cell subset development. *Semin Immunol* **23**, 146–153.
168. Olszak T, An D, Zeissig S, *et al.* (2012) Microbial exposure during early life has persistent effects on natural killer T cell function. *Science* **336**, 489–493.
169. Noval Rivas M, Burton OT, Wise P, *et al.* (2013) A microbiota signature associated with experimental food allergy promotes allergic sensitization and anaphylaxis. *J Allergy Clin Immunol* **131**, 201–212.
170. Konieczna P, Akdis CA, Quigley EM, *et al.* (2012) Portrait of an immunoregulatory *Bifidobacterium*. *Gut Microbes* **3**, 261–266.
171. O'Mahony C, Scully P, O'Mahony D, *et al.* (2008) Commensal-induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation. *PLoS Pathog* **4**, e1000112.
172. Groeger D, O'Mahony L, Murphy EF, *et al.* (2013) *Bifidobacterium infantis* 35624 modulates host inflammatory processes beyond the gut. *Gut Microbes* **4**, 325–339.
173. Konieczna P, Groeger D, Ziegler M, *et al.* (2012) *Bifidobacterium infantis* 35624 administration induces Foxp3 T regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells. *Gut* **61**, 354–366.
174. Lyons A, O'Mahony D, O'Brien F, *et al.* (2010) Bacterial strain-specific induction of Foxp3+ T regulatory cells is protective in murine allergy models. *Clin Exp Allergy* **40**, 811–819.
175. O'Mahony L, Akdis M & Akdis CA (2011) Regulation of the immune response and inflammation by histamine and histamine receptors. *J Allergy Clin Immunol* **128**, 1153–1162.
- 1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490



- 1491 176. Frei R, Ferstl R, Konieczna P, *et al.* (2013) Histamine receptor
1492 2 modifies dendritic cell responses to microbial ligands.
1493 *J Allergy Clin Immunol* **132**, 194–204.
1494 177. Ferstl R, Frei R, Schiavi E, *et al.* (2014) Histamine receptor 2 is
1495 a key influence in immune responses to intestinal histamine-
1496 secreting microbes. *J Allergy Clin Immunol* **134**, 744–746.
1497 178. Roduit C, Frei R, Loss G, *et al.* (2012) Development of atopic
1498 dermatitis according to age of onset and association with
1499 early-life exposures. *J Allergy Clin Immunol* **130**, 130–136.
1500 179. Young KT, Davis LM & Dirita VJ (2007) *Campylobacter*
1501 *jejuni*: molecular biology and pathogenesis. *Nat Rev Micro-*
1502 *biol* **5**, 665–679.
1503 180. Bereswill S, Fischer A, Plickert R, *et al.* (2011) Novel murine
1504 infection models provide deep insights into the ‘menage a
1505 trois’ of *Campylobacter jejuni*, microbiota and host innate
1506 immunity. *PLoS ONE* **6**, e20953.
1507 181. Heimesaat MM, Plickert R, Fischer A, *et al.* (2013) Can
1508 microbiota transplantation abrogate murine colonization
1509 resistance against *Campylobacter jejuni*? *Eur J Microbiol*
1510 *Immunol (Bp)* **3**, 36–43.
1511 182. Haag LM, Fischer A, Otto B, *et al.* (2012) Intestinal microbiota
1512 shifts towards elevated commensal *Escherichia coli* loads
1513 abrogate colonization resistance against *Campylobacter*
1514 *jejuni* in mice. *PLoS ONE* **7**, e35988.
1515 183. Heimesaat MM & Bereswill S (2015) Murine infection models for
1516 the investigation of *Campylobacter jejuni* – host interactions and
1517 pathogenicity. *Berl Munch Tierarztl Wochenschr* **128**, 98–103.
1518 184. Haag LM, Fischer A, Otto B, *et al.* (2012) *Campylobacter*
1519 *jejuni* induces acute enterocolitis in gnotobiotic IL-10^{-/-} mice
1520 via toll-like-receptor-2 and -4 signaling. *PLoS ONE* **7**, e40761.
1521 185. Mortensen NP, Kuijff ML, Ang CW, *et al.* (2009) Sialylation of
1522 *Campylobacter jejuni* lipo-oligosaccharides is associated
1523 with severe gastro-enteritis and reactive arthritis. *Microbes*
1524 *Infect* **11**, 988–994.
1525 186. Edwards LA, Nistala K, Mills DC, *et al.* (2010) Delineation of
1526 the innate and adaptive T-cell immune outcome in the
1527 human host in response to *Campylobacter jejuni* infection.
1528 *PLoS ONE* **5**, e15398.
1529 187. Kholy KE, Genco RJ & Van Dyke TE (2015) Oral infections and
1530 cardiovascular disease. *Trends Endocrinol Metab* **26**, 315–321.
1531 188. Hajishengallis G (2015) Periodontitis: from microbial immune
1532 subversion to systemic inflammation. *Nat Rev Immunol* **15**,
1533 30–44.
1534 189. Olsen I (2015) From the acta prize lecture 2014: the
1535 periodontal-systemic connection seen from a microbiological
1536 standpoint. *Acta Odontol Scand* **73**, 563–568.
1537 190. Niederman R, Buyle-Bodin Y, Lu BY, *et al.* (1997) Short-
1538 chain carboxylic acid concentration in human gingival
1539 crevicular fluid. *J Dent Res* **76**, 575–579.
1540 191. Kurita-Ochiai T, Fukushima K & Ochiai K (1995) Volatile fatty
1541 acids, metabolic by-products of periodontopathic bacteria,
1542 inhibit lymphocyte proliferation and cytokine production.
1543 *J Dent Res* **74**, 1367–1373.
1544 192. Yoneda S, Kawarai T, Narisawa N, *et al.* (2013) Effects of
1545 short-chain fatty acids on *Actinomyces naeslundii* biofilm
1546 formation. *Mol Oral Microbiol* **28**, 354–365.
1547 193. Arai T, Ochiai K & Senpuku H (2015) *Actinomyces naeslundii*
1548 GroEL-dependent initial attachment and biofilm formation in a
1549 flow cell system. *J Microbiol Methods* **109**, 160–166.
1550 194. Kurita-Ochiai T, Ochiai K & Fukushima K (2000) Butyric-
1551 acid-induced apoptosis in murine thymocytes and splenic
1552 T- and B-cells occurs in the absence of p53. *J Dent Res* **79**,
1553 1948–1954.
1554 195. Kurita-Ochiai T, Amano S, Fukushima K, *et al.* (2003) Cellular
1555 events involved in butyric acid-induced T cell apoptosis.
1556 *J Immunol* **171**, 3576–3584.
196. Kurita-Ochiai T, Seto S & Ochiai K (2004) Role of cell-cell
1557 communication in inhibiting butyric acid-induced T-cell
1558 apoptosis. *Infect Immun* **72**, 5947–5954.
1559 197. Kurita-Ochiai T, Seto S, Suzuki N, *et al.* (2008) Butyric acid
1560 induces apoptosis in inflamed fibroblasts. *J Dent Res* **87**, 51–55.
1561 198. Cueno ME, Imai K, Tamura M, *et al.* (2014) Butyric acid-
1562 induced rat jugular blood cytosolic oxidative stress is associated
1563 with SIRT1 decrease. *Cell Stress Chaperones* **19**, 295–298.
1564 199. Cueno ME, Tamura M & Ochiai K (2015) Middle-aged rats
1565 orally supplemented with gel-encapsulated catechin favor-
1566 ably increases blood cytosolic NADPH levels. *Phytomedicine*
1567 **22**, 425–430.
1568 200. Imai K, Yamada K, Tamura M, *et al.* (2012) Reactivation of
1569 latent HIV-1 by a wide variety of butyric acid-producing
1570 bacteria. *Cell Mol Life Sci* **69**, 2583–2592.
1571 201. Cueno ME, Imai K, Matsukawa N, *et al.* (2013) Butyric acid
1572 retention in gingival tissue induces oxidative stress in jugular
1573 blood mitochondria. *Cell Stress Chaperones* **18**, 661–665.
1574 202. Cueno ME, Tamura M, Ohya M, *et al.* (2014) Similar
1575 physiological effects in *Porphyromonas gingivalis* ATCC
1576 33277 under hemin-excess and hemin-limited concentrations
1577 are putatively associated to different hydrogen peroxide
1578 function. *Anaerobe* **28**, 178–181.
1579 203. Cornelius C, Koverech G, Crupi R, *et al.* (2014) Osteoporosis
1580 and Alzheimer pathology: role of cellular stress response and
1581 hormetic redox signaling in aging and bone remodeling.
1582 *Front Pharmacol* **5**, 120.
1583 204. Cueno ME, Kamio N, Seki K, *et al.* (2015) High butyric acid
1584 amounts induce oxidative stress, alter calcium homeostasis,
1585 and cause neurite retraction in nerve growth factor-treated
1586 PC12 cells. *Cell Stress Chaperones* **20**, 709–713.
1587 205. Shalini S, Dorstyn L, Dawar S, *et al.* (2015) Old, new and
1588 emerging functions of caspases. *Cell Death Differ* **22**, 526–539.
1589 206. Maticic M, Poljak M, Kramar B, *et al.* (2000) Proviral HIV-1
1590 DNA in gingival crevicular fluid of HIV-1-infected patients in
1591 various stages of HIV disease. *J Dent Res* **79**, 1496–1501.
1592 207. Imai K, Ochiai K & Okamoto T (2009) Reactivation of
1593 latent HIV-1 infection by the periodontopathic bacterium
1594 *Porphyromonas gingivalis* involves histone modification.
1595 *J Immunol* **182**, 3688–3695.
1596 208. Saygun I, Nizam N, Keskiner I, *et al.* (2011) Salivary infectious
1597 agents and periodontal disease status. *J Periodontol Res* **46**,
1598 235–239.
1599 209. Konstantinidis A, Sakellari D, Papa A, *et al.* (2005) Real-time
1600 polymerase chain reaction quantification of Epstein-Barr
1601 virus in chronic periodontitis patients. *J Periodontol Res* **40**,
1602 294–298.
1603 210. Imai K, Inoue H, Tamura M, *et al.* (2012) The periodontal
1604 pathogen *Porphyromonas gingivalis* induces the Epstein-
1605 Barr virus lytic switch transactivator ZEBRA by histone
1606 modification. *Biochimie* **94**, 839–846.
1607 211. Segers ME & Lebeer S (2014) Towards a better understanding
1608 of *Lactobacillus rhamnosus* GG – host interactions. *Microb*
1609 *Cell Fact* **13**, Suppl. 1, S7.
1610 212. Elazab N, Mendy A, Gasana J, *et al.* (2013) Probiotic
1611 administration in early life, atopy, and asthma: a meta-
1612 analysis of clinical trials. *Pediatrics* **132**, e666–e676.
1613 213. World Health Organization, Food and Agricultural Organization
1614 of the United Nations (2006) *Probiotics in Food. Health and*
1615 *Nutritional Properties and Guidelines for Evaluation*. FAO
1616 *Nutrition Paper*, 85. Rome: FAO.
1617 214. Hill C, Guarner F, Reid G, *et al.* (2014) Expert consensus
1618 document. The International Scientific Association for Probiotics
1619 and Prebiotics consensus statement on the scope and
1620 appropriate use of the term probiotic. *Nat Rev Gastroenterol*
1621 *Hepatol* **11**, 506–514.
1622



- 1623 215. Binnendijk KH & Rijkers GT (2013) What is a health
1624 benefit? An evaluation of EFSA opinions on health
1625 benefits with reference to probiotics. *Benef Microbes* **4**,
1626 223–230.
- 1627 216. Petrof EO, Gloor GB, Vanner SJ, *et al.* (2013) Stool substitute
1628 transplant therapy for the eradication of *Clostridium difficile*
1629 infection: 'RePOOPulating' the gut. *Microbiome* **1**, 3.
217. Ritchie ML & Romanuk TN (2012) A meta-analysis of probiotic
1630 efficacy for gastrointestinal diseases. *PLOS ONE* **7**, e34938. 1631
218. Canadian Food Inspection Agency (2015) Probiotic claims.
1632 Acceptable non-strain specific claims. [http://inspection.gc-](http://inspection.gc.ca/food/labelling/food-labelling-for-industry/health-claims/eng/1392834838383/1392834887794?chap=9#s21c9)
1633 [ca/food/labelling/food-labelling-for-industry/health-claims/](http://inspection.gc.ca/food/labelling/food-labelling-for-industry/health-claims/eng/1392834838383/1392834887794?chap=9#s21c9)
1634 [eng/1392834838383/1392834887794?chap=9#s21c9](http://inspection.gc.ca/food/labelling/food-labelling-for-industry/health-claims/eng/1392834838383/1392834887794?chap=9#s21c9) (acces-
1635 sed July 2015). 1636